Literature DB >> 23873233

Induction of SHP2 deficiency in chondrocytes causes severe scoliosis and kyphosis in mice.

Harry K W Kim1, Olumide Aruwajoye, Daniel Sucato, B Stephens Richards, Gen-Sheng Feng, Di Chen, Philip D King, Nobuhiro Kamiya.   

Abstract

STUDY
DESIGN: Genetic engineering techniques were used to develop an animal model of juvenile scoliosis during a postnatal skeletal-growth stage.
OBJECTIVE: To investigate the effect of targeted SHP2 (Src homology-2) deficiency in chondrocytes on the development of scoliosis during a juvenile growth stage in mice. SUMMARY OF BACKGROUND DATA: Juvenile idiopathic scoliosis can lead to progressive severe spinal deformity. The pathophysiology and molecular mechanisms responsible for the deformity are unknown. Here, we investigated the role of SHP2 deficiency in chondrocytes as a potential cause of juvenile scoliosis.
METHODS: Genetically engineered mice with inducible deletion of SHP2 in chondrocytes were generated. The SHP2 function in chondrocytes was inactivated during a juvenile growth stage from the mouse age of 4 weeks. Radiographical, micro-computed tomographic, and histological assessments were used to analyze spinal changes.
RESULTS: When SHP2 deficiency was induced during the juvenile stage, a progressive kyphoscoliotic deformity (thoracic lordosis and thoracolumbar kyphoscoliosis) developed within 2 weeks of the initiation of SHP2 deficiency. The 3-dimensional micro-computed tomography analysis confirmed the kyphoscoliotic deformity with a rotational deformity of the spine and osteophyte formation. The histological analysis revealed disorganization of the vertebral growth plate cartilage. Interestingly, when SHP2 was disrupted during the adolescent to adult stages, no spinal deformity developed.
CONCLUSION: SHP2 plays an important role in normal spine development during skeletal maturation. Chondrocyte-specific deletion of SHP2 at a juvenile stage produced a kyphoscoliotic deformity. This new mouse model will be useful for future investigations of the role of SHP2 deficiency in chondrocytes as a mechanism leading to the development of juvenile scoliosis. LEVEL OF EVIDENCE: N/A.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23873233      PMCID: PMC3864111          DOI: 10.1097/BRS.0b013e3182a3d370

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  11 in total

Review 1.  Developmental regulation of the growth plate.

Authors:  Henry M Kronenberg
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

2.  Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome.

Authors:  Pablo Rodriguez-Viciana; Osamu Tetsu; William E Tidyman; Anne L Estep; Brenda A Conger; Molly Santa Cruz; Frank McCormick; Katherine A Rauen
Journal:  Science       Date:  2006-01-26       Impact factor: 47.728

3.  Spinal deformities in Noonan syndrome: a clinical review of sixty cases.

Authors:  C K Lee; B S Chang; Y M Hong; S W Yang; C S Lee; J B Seo
Journal:  J Bone Joint Surg Am       Date:  2001-10       Impact factor: 5.284

4.  Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome.

Authors:  M Tartaglia; E L Mehler; R Goldberg; G Zampino; H G Brunner; H Kremer; I van der Burgt; A H Crosby; A Ion; S Jeffery; K Kalidas; M A Patton; R S Kucherlapati; B D Gelb
Journal:  Nat Genet       Date:  2001-12       Impact factor: 38.330

5.  Disruption of BMP signaling in osteoblasts through type IA receptor (BMPRIA) increases bone mass.

Authors:  Nobuhiro Kamiya; Ling Ye; Tatsuya Kobayashi; Donald J Lucas; Yoshiyuki Mochida; Mitsuo Yamauchi; Henry M Kronenberg; Jian Q Feng; Yuji Mishina
Journal:  J Bone Miner Res       Date:  2008-12       Impact factor: 6.741

6.  A novel PTPN11 mutation in LEOPARD syndrome.

Authors:  E Conti; T Dottorini; A Sarkozy; G E Tiller; G Esposito; A Pizzuti; B Dallapiccola
Journal:  Hum Mutat       Date:  2003-06       Impact factor: 4.878

7.  Loss of NF1 results in activation of the Ras signaling pathway and leads to aberrant growth in haematopoietic cells.

Authors:  G Bollag; D W Clapp; S Shih; F Adler; Y Y Zhang; P Thompson; B J Lange; M H Freedman; F McCormick; T Jacks; K Shannon
Journal:  Nat Genet       Date:  1996-02       Impact factor: 38.330

Review 8.  The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation.

Authors:  William E Tidyman; Katherine A Rauen
Journal:  Curr Opin Genet Dev       Date:  2009-05-19       Impact factor: 5.578

9.  Development of severe skeletal defects in induced SHP-2-deficient adult mice: a model of skeletal malformation in humans with SHP-2 mutations.

Authors:  Timothy J Bauler; Nobuhiro Kamiya; Philip E Lapinski; Eric Langewisch; Yuji Mishina; John E Wilkinson; Gen-Sheng Feng; Philip D King
Journal:  Dis Model Mech       Date:  2010-11-10       Impact factor: 5.758

10.  Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts.

Authors:  Nobuhiro Kamiya; Tatsuya Kobayashi; Yoshiyuki Mochida; Paul B Yu; Mitsuo Yamauchi; Henry M Kronenberg; Yuji Mishina
Journal:  J Bone Miner Res       Date:  2010-02       Impact factor: 6.741

View more
  11 in total

1.  Noonan syndrome-causing SHP2 mutants impair ERK-dependent chondrocyte differentiation during endochondral bone growth.

Authors:  Mylène Tajan; Julie Pernin-Grandjean; Nicolas Beton; Isabelle Gennero; Florence Capilla; Benjamin G Neel; Toshiyuki Araki; Philippe Valet; Maithé Tauber; Jean-Pierre Salles; Armelle Yart; Thomas Edouard
Journal:  Hum Mol Genet       Date:  2018-07-01       Impact factor: 6.150

Review 2.  Col2CreER(T2), a mouse model for a chondrocyte-specific and inducible gene deletion.

Authors:  M Chen; S Li; W Xie; B Wang; D Chen
Journal:  Eur Cell Mater       Date:  2014-10-23       Impact factor: 3.942

Review 3.  Role of Primary Cilia in Skeletal Disorders.

Authors:  Xinhua Li; Song Guo; Yang Su; Jiawei Lu; Donghua Hang; Shao Cao; Qiang Fu; Ziqing Li
Journal:  Stem Cells Int       Date:  2022-06-18       Impact factor: 5.131

4.  Deletion of SHP-2 in mesenchymal stem cells causes growth retardation, limb and chest deformity, and calvarial defects in mice.

Authors:  Philip E Lapinski; Melissa F Meyer; Gen-Sheng Feng; Nobuhiro Kamiya; Philip D King
Journal:  Dis Model Mech       Date:  2013-09-25       Impact factor: 5.758

5.  Micro CT Analysis of Spine Architecture in a Mouse Model of Scoliosis.

Authors:  Chan Gao; Brian P Chen; Michael B Sullivan; Jasmine Hui; Jean A Ouellet; Janet E Henderson; Neil Saran
Journal:  Front Endocrinol (Lausanne)       Date:  2015-03-19       Impact factor: 5.555

6.  Site-1 protease regulates skeletal stem cell population and osteogenic differentiation in mice.

Authors:  Debabrata Patra; Elizabeth DeLassus; Jennifer Mueller; Grazia Abou-Ezzi; Linda J Sandell
Journal:  Biol Open       Date:  2018-02-22       Impact factor: 2.422

7.  Regulation of terminal hypertrophic chondrocyte differentiation in Prmt5 mutant mice modeling infantile idiopathic scoliosis.

Authors:  Zhaoyang Liu; Janani Ramachandran; Steven A Vokes; Ryan S Gray
Journal:  Dis Model Mech       Date:  2019-12-17       Impact factor: 5.758

8.  Targeting chondrocytes for arresting bony fusion in ankylosing spondylitis.

Authors:  Fenli Shao; Qianqian Liu; Yuyu Zhu; Zhidan Fan; Wenjun Chen; Shijia Liu; Xiaohui Li; Wenjie Guo; Gen-Sheng Feng; Haiguo Yu; Qiang Xu; Yang Sun
Journal:  Nat Commun       Date:  2021-11-11       Impact factor: 14.919

9.  SHP2 regulates chondrocyte terminal differentiation, growth plate architecture and skeletal cell fates.

Authors:  Margot E Bowen; Ugur M Ayturk; Kyle C Kurek; Wentian Yang; Matthew L Warman
Journal:  PLoS Genet       Date:  2014-05-29       Impact factor: 5.917

10.  SHP2 Regulates the Osteogenic Fate of Growth Plate Hypertrophic Chondrocytes.

Authors:  Lijun Wang; Jiahui Huang; Douglas C Moore; Chunlin Zuo; Qian Wu; Liqin Xie; Klaus von der Mark; Xin Yuan; Di Chen; Matthew L Warman; Michael G Ehrlich; Wentian Yang
Journal:  Sci Rep       Date:  2017-10-05       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.